Posted by Michael Wonder on 10 Apr 2026
Cemiplimab in cutaneous squamous cell carcinoma: no suitable data due to insufficient observation period
16 March 2026 - To rule out a recurrence, patients must be monitored for a sufficient period of time, even after the end of therapy. This is not always the case in the manufacturers' studies.
The example of cemiplimab in squamous cell carcinoma of the skin illustrates this point.
